Premium
Hypolipidemic and thyroid hormone effects of sodium dextrotriiodothyronine
Author(s) -
Danowski T. S.,
Sunder J. H.,
Corredor D. G.,
Jung Y.,
Vester J. W.,
Khurana R. C.,
Wingert J. P.
Publication year - 1971
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1971121126
Subject(s) - euthyroid , medicine , chemistry , endocrinology , triiodothyronine , globulin , iodine , thyroid , sodium , urine , hormone , blood proteins , organic chemistry
Sodium dextrotriiodothyronine (Na‐DT 3 ) at a dosage of 1 mg. per day for 24 weeks produced an approximately 75 mg. per cent decrease in serum total cholesterol in hyper‐and normolipidemic subjects. Na‐DT 3 usually lowered the level of serum leva‐thyroxine (LT 4 ) to the myxedema range, but the subjects remained euthyroid, suggesting that Na‐DT 3 was exerting a thyroid hormone‐replacement effect. The failure to observe the changes to be expected in the in vitro levo‐triiodothyronine (LT 3 ) uptake by blood cells when the serum protein‐bound iodine (PBI) had increased indicates that perhaps Na‐DT 3 occupies binding sites other than those used by LT 3 that Na‐DT 3 is loosely bound to plasma proteins and is readily displaced by LT 3 , or both. An unexplained rise in urine total protein was observed during the first 6 weeks of Na‐DT 3 therapy but not at 12 weeks. Serum total globulins were increased in the twenty‐fourth week. Minor changes within the normal range were recorded in plasma 11(OH)‐corticosteroids and in urine Porter‐Silber chromogens. All other indices remained within the pretherapy range.